Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse

被引:6
作者
Salhotra, Amandeep [1 ]
Stein, Anthony Selwyn [1 ]
机构
[1] City Hope Natl Canc Ctr, Dept Hematol Hematopoiet Cell Transplant HCT, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
leukemia; HCT; TBI; TMLI; relapse; STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; ACUTE MYELOID-LEUKEMIA; TOTAL-MARROW IRRADIATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; GUIDED TOTAL-MARROW; REDUCED-INTENSITY; PLUS CYCLOPHOSPHAMIDE;
D O I
10.3389/fonc.2022.802648
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the two decades there has been a consistent improvement in the clinical outcomes of patients diagnosed with acute leukemia undergoing allogenic stem cell transplantation. These improvements have been made possible by advancements in supportive care practices, more precise risk stratification of leukemia patients by genetic testing at diagnosis, accurate disease assessment by measurable residual disease (MRD) in pretransplant marrow and attempts to clear residual disease clones prior to transplant. Availability of targeted therapies, immunotherapies, and approval of novel drug combinations with BCL-2 inhibitors has also improved remission rates for patients who are undergoing transplant. For patients who are unable to achieve a morphologic or MRD- remission prior to transplant, the risk of relapse post-transplant remains high. Total body irradiation (TBI) based intensification of transplant conditioning may be able to overcome risk of increased relapse rate in this clinical setting by improving clearance of leukemic clones. However, in the past increased nonrelapse mortality (NRM) associated with escalation of conditioning intensity has neutralized any potential benefit of decreasing relapse rate in HCT patient resulting in no significant improvement in overall survival. In this review we discuss incorporation of newer radiation techniques such as total marrow irradiation (TMI) to safely deliver targeted doses of radiation at higher doses to improve outcomes of patients with active leukemia. We also discuss the mechanisms associated with leukemia relapse and treatment options available in post allo-HCT relapse setting despite use of intensified conditioning regimens.
引用
收藏
页数:17
相关论文
共 96 条
[1]   The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells [J].
Almstedt, Maika ;
Blagitko-Dorfs, Nadja ;
Duque-Afonso, Jesus ;
Karbach, Julia ;
Pfeifer, Dietmar ;
Jaeger, Elke ;
Luebbert, Michael .
LEUKEMIA RESEARCH, 2010, 34 (07) :899-905
[2]  
[Anonymous], 2016, N Engl J Med, V375, P2010
[3]   CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].
Bashey, Asad ;
Medina, Bridget ;
Corringham, Sue ;
Pasek, Mildred ;
Carrier, Ewa ;
Vrooman, Linda ;
Lowy, Israel ;
Solomon, Scott R. ;
Morris, Lawrence E. ;
Holland, H. Kent ;
Mason, James R. ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Ball, Edward D. .
BLOOD, 2009, 113 (07) :1581-1588
[4]  
BLAISE D, 1992, BLOOD, V79, P2578
[5]   Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts [J].
Bleakley, Marie ;
Heimfeld, Shelly ;
Loeb, Keith R. ;
Jones, Lori A. ;
Chaney, Colette ;
Seropian, Stuart ;
Cooley, Ted A. ;
Sommermeyer, Franziska ;
Riddell, Stanley R. ;
Shlomchik, Warren D. .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (07) :2677-2689
[6]   Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naive T Cells and Retain Functional Pathogen-Specific Memory T Cells [J].
Bleakley, Marie ;
Heimfeld, Shelly ;
Jones, Lori A. ;
Turtle, Cameron ;
Krause, Diane ;
Riddell, Stanley R. ;
Shlomchik, Warren .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (05) :705-716
[7]   Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation [J].
Bredeson, Christopher ;
LeRademacher, Jennifer ;
Kato, Kazunobu ;
DiPersio, John F. ;
Agura, Edward ;
Devine, Steven M. ;
Appelbaum, Frederick R. ;
Tomblyn, Marcie R. ;
Laport, Ginna G. ;
Zhu, Xiaochun ;
McCarthy, Philip L. ;
Ho, Vincent T. ;
Cooke, Kenneth R. ;
Armstrong, Elizabeth ;
Smith, Angela ;
Rizzo, J. Douglas ;
Burkart, Jeanne M. ;
Pasquini, Marcelo C. .
BLOOD, 2013, 122 (24) :3871-3878
[8]   HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP [J].
BROWN, RA ;
WOLFF, SN ;
FAY, JW ;
PINEIRO, L ;
COLLINS, RH ;
LYNCH, JP ;
STEVENS, D ;
GREER, J ;
HERZIG, RH ;
HERZIG, GP .
BLOOD, 1995, 85 (05) :1391-1395
[9]   Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) [J].
Bug, G. ;
Burchert, A. ;
Wagner, E-M ;
Kroeger, N. ;
Berg, T. ;
Gueller, S. ;
Metzelder, S. K. ;
Wolf, A. ;
Huenecke, S. ;
Bader, P. ;
Schetelig, J. ;
Serve, H. ;
Ottmann, O. G. .
LEUKEMIA, 2017, 31 (11) :2523-2525
[10]   MYC regulates the antitumor immune response through CD47 and PD-L1 [J].
Casey, Stephanie C. ;
Tong, Ling ;
Li, Yulin ;
Do, Rachel ;
Walz, Susanne ;
Fitzgerald, Kelly N. ;
Gouw, Arvin M. ;
Baylot, Virginie ;
Guetgemann, Ines ;
Eilers, Martin ;
Felsher, Dean W. .
SCIENCE, 2016, 352 (6282) :227-231